Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00120835 · ClinicalTrials.gov registry record · Phase 1
Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00120835 is a Phase 1 study that has completed, run by Merck Sharp & Dohme.
The verdict
NCT00120835, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
This study is being conducted in treatment-naive patients (no previous hepatitis C treatment) to evaluate the safety of valopicitabine (NM283) alone and together with pegylated interferon, a drug approved by the Food and Drug Administration for the treatment of hepatitis C infection. This study is also evaluating the ability of valopicitabine to decrease the amount of hepatitis C virus in the body. The results for patients taking valopicitabine alone will be compared with the results for patients taking valopicitabine together with pegylated interferon.
Interventions
- DRUG valopicitabine
- DRUG pegylated interferon
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00120835
The ClinicalTrials.gov registry entry for NCT00120835 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which valopicitabine is the first listed.
NCT00120835 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00120835 about?
NCT00120835 is a clinical study titled "Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C". This study is being conducted in treatment-naive patients (no previous hepatitis C treatment) to evaluate the safety of valopicitabine (NM283) alone and together with pegylated interferon, a drug approved by the Food and Drug Administration for the treatment of hepatitis C infection. This study is a...
What is the current status of trial NCT00120835?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-07.
What interventions are being tested in trial NCT00120835?
The interventions under investigation include: valopicitabine (DRUG), pegylated interferon (DRUG).
Who is sponsoring clinical trial NCT00120835?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.